Gerresheimer AG (GRRMF) Income Statement Analysis

See more : Janus Henderson Sustainable Cor (JLQD) Income Statement Analysis – Financial Results

Complete financial analysis of Gerresheimer AG (GRRMF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gerresheimer AG, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Finatext Holdings Ltd. (4419.T) Income Statement Analysis – Financial Results
Lionhead Technology Development Co., Ltd. (600539.SS) Income Statement Analysis – Financial Results
Emeco Holdings Limited (EHL.AX) Income Statement Analysis – Financial Results
Global SPAC Partners Co. (GLSPT) Income Statement Analysis – Financial Results
Emmis Corporation (EMMS) Income Statement Analysis – Financial Results

Gerresheimer AG (GRRMF)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.gerresheimer.com

About Gerresheimer AG

Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	1.99B	1.82B	1.50B	1.42B	1.39B	1.37B	1.35B	1.38B	1.38B	1.29B	1.27B	1.22B	1.09B	1.02B	1.00B	1.06B	957.70M	0.00	0.00
Cost of Revenue	1.39B	1.27B	1.06B	981.18M	1.12B	967.60M	934.42M	943.72M	972.24M	933.89M	901.71M	861.63M	773.53M	719.02M	734.96M	766.84M	683.50M	-474.14M	-376.38M
Gross Profit	597.31M	546.81M	442.23M	437.61M	277.19M	400.13M	413.84M	431.75M	405.00M	356.12M	364.22M	357.44M	321.15M	305.78M	265.26M	293.26M	274.20M	474.14M	376.38M
Gross Profit Ratio	30.01%	30.09%	29.52%	30.84%	19.91%	29.26%	30.69%	31.39%	29.41%	27.61%	28.77%	29.32%	29.34%	29.84%	26.52%	27.66%	28.63%	0.00%	0.00%
Research & Development	18.97M	21.62M	10.00M	7.66M	3.59M	2.92M	3.51M	3.16M	1.85M	1.50M	2.15M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	326.02M	304.64M	244.73M	233.38M	234.14M	0.00	0.00	0.00	0.00	6.38M	0.00	220.77M	212.62M	207.93M	73.81M	74.63M	70.68M	0.00	0.00
Selling & Marketing	46.60M	304.64M	247.11M	232.51M	233.30M	259.41M	255.57M	255.37M	262.01M	222.11M	231.16M	0.00	0.00	0.00	123.00M	132.42M	93.96M	-64.07M	-52.38M
SG&A	372.62M	304.64M	247.11M	232.51M	233.30M	259.41M	255.57M	255.37M	262.01M	222.11M	231.16M	220.77M	212.62M	207.93M	196.81M	207.04M	164.65M	-64.07M	-52.38M
Other Expenses	-7.66M	1.26M	6.29M	17.51M	7.68M	4.68M	6.26M	643.00K	-19.62M	3.04M	-4.75M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	383.92M	327.51M	263.40M	257.67M	244.57M	244.31M	238.42M	251.91M	253.36M	217.60M	225.46M	228.41M	211.88M	207.06M	201.28M	227.19M	208.16M	-64.07M	-52.38M
Cost & Expenses	1.78B	1.60B	1.32B	1.24B	1.36B	1.21B	1.17B	1.20B	1.23B	1.15B	1.13B	1.09B	985.41M	926.08M	936.25M	994.04M	891.66M	-538.21M	-428.76M
Interest Income	3.80M	1.98M	1.33M	1.46M	2.65M	2.44M	4.36M	4.76M	4.82M	3.50M	2.82M	3.46M	2.31M	935.00K	1.38M	1.93M	12.08M	0.00	0.00
Interest Expense	50.44M	27.96M	20.70M	20.76M	24.70M	29.75M	35.00M	34.04M	39.37M	34.04M	37.02M	36.74M	39.07M	35.26M	41.67M	45.60M	89.65M	0.00	0.00
Depreciation & Amortization	186.03M	220.51M	177.29M	167.14M	269.95M	137.06M	124.81M	125.71M	108.55M	104.26M	82.93M	100.04M	101.03M	105.82M	114.51M	109.40M	98.15M	72.95M	113.37M
EBITDA	403.89M	340.32M	293.93M	301.41M	296.66M	274.00M	305.33M	306.68M	289.63M	237.65M	218.70M	219.76M	210.88M	201.79M	176.30M	172.30M	163.55M	102.85M	542.13M
EBITDA Ratio	20.29%	21.45%	21.68%	22.81%	21.31%	21.25%	22.28%	22.29%	19.29%	19.11%	17.69%	18.79%	19.42%	20.05%	17.99%	16.73%	18.50%	0.00%	0.00%
Operating Income	213.39M	169.31M	147.44M	156.46M	26.71M	139.46M	180.80M	180.47M	193.57M	129.90M	132.95M	128.46M	109.27M	95.03M	60.42M	60.97M	53.32M	21.81M	-30.62M
Operating Income Ratio	10.72%	9.32%	9.84%	11.03%	1.92%	10.20%	13.41%	13.12%	14.06%	10.07%	10.50%	10.54%	9.98%	9.27%	6.04%	5.75%	5.57%	0.00%	0.00%
Total Other Income/Expenses	-45.96M	-28.50M	-19.58M	-21.32M	-25.59M	-32.26M	-35.31M	-33.53M	-34.60M	-30.55M	-34.19M	-33.28M	-36.75M	-34.32M	-40.30M	-43.67M	-77.57M	-53.94M	0.00
Income Before Tax	167.43M	140.81M	127.87M	135.15M	98.17M	107.20M	145.49M	146.94M	159.01M	99.35M	98.75M	95.75M	72.52M	60.70M	20.12M	17.30M	-24.25M	0.00	0.00
Income Before Tax Ratio	8.41%	7.75%	8.54%	9.53%	7.05%	7.84%	10.79%	10.68%	11.55%	7.70%	7.80%	7.85%	6.62%	5.92%	2.01%	1.63%	-2.53%	0.00%	0.00%
Income Tax Expense	47.34M	38.62M	40.62M	45.26M	15.49M	-23.93M	42.44M	42.46M	46.36M	26.50M	30.27M	29.24M	18.09M	13.96M	13.16M	12.79M	-25.09M	0.00	0.00
Net Income	116.13M	96.12M	83.79M	88.56M	80.78M	128.97M	100.89M	121.64M	104.22M	66.34M	62.16M	60.19M	54.43M	46.75M	6.96M	4.51M	-1.23M	0.00	0.00
Net Income Ratio	5.83%	5.29%	5.59%	6.24%	5.80%	9.43%	7.48%	8.84%	7.57%	5.14%	4.91%	4.94%	4.97%	4.56%	0.70%	0.43%	-0.13%	0.00%	0.00%
EPS	3.48	3.06	2.67	2.82	2.57	4.11	3.21	3.87	3.32	2.11	1.98	1.98	1.61	1.38	0.18	0.02	-0.04	0.00	0.00
EPS Diluted	3.48	3.06	2.67	2.82	2.57	4.11	3.21	3.87	3.32	2.11	1.98	1.98	1.61	1.38	0.18	0.02	-0.04	0.00	0.00
Weighted Avg Shares Out	33.34M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	0.00
Weighted Avg Shares Out (Dil)	33.34M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	31.40M	0.00

Gerresheimer shares jump as activist investor buys over 5% stake

October 9, 2024reuters.com

Gerresheimer's shares rose as much as 6.8% on Wednesday after a regulatory filing showed activist investor Ricky Chad Sandler had bought a 5.43% stake in German medical packaging maker.

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”

September 26, 2024businesswire.com

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co....

Gerresheimer AG (GRRMF) Q2 2024 Earnings Call Transcript

July 11, 2024seekingalpha.com

Gerresheimer AG (OTCPK:GRRMF) Q2 2024 Earnings Conference Call July 11, 2024 4:00 AM ET Company Participants Guido Pickert - IR Dietmar Siemssen - CEO Bernd Metzner - CFO Conference Call Participants Oliver Reinberg - Kepler Cheuvreux Victoria Lambert - Berenberg...

Gerresheimer core profit meets forecast on weight-loss drug deals pipeline

July 11, 2024reuters.com

Germany's Gerresheimer posted second-quarter adjusted core profit in line with market expectations on Thursday, driven by the deal pipeline for its plastics and devices segment, which supplies makers of weight-loss drugs with autoinjector pens.

Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says

April 11, 2024reuters.com

German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.

Gerresheimer expects sales boost from burgeoning obesity drugs sector

April 11, 2024reuters.com

German packaging and medical equipment maker Gerresheimer on Thursday posted adjusted first-quarter core profit in line with expectations of analysts polled by Vara Research, driven by the plastics and devices division.

Gerresheimer Makes Solid Start to the Financial Year 2024

April 11, 2024accesswire.com

Organic growth: Revenues +2.8%, adjusted EBITDA +5.9% Capacity expansion in the Americas, Europe and Asia progresses according to plan Guidance confirmed DUSSELDORF, GERMANY / ACCESSWIRE / April 11, 2024 / Gerresheimer, an innovative systems and solutions provider and a global...

Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst

March 31, 2024invezz.com

Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company. Weight-loss drugs to boost $GXI revenue growth Siemssen expects supply of vials, syringes, cartridges, and...

Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

March 29, 2024reuters.com

Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors.